Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance
| Autor: | Esperanza Martínez-Abundis, Manuel González-Ortiz, Eduardo Hernández-Salazar, Angélica M. Kam-Ramos |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Endocrinology Diabetes and Metabolism Body Mass Index Impaired glucose tolerance Placebos chemistry.chemical_compound Endocrinology Double-Blind Method Diabetes mellitus Internal medicine Glucose Intolerance Insulin Secretion Internal Medicine medicine Humans Hypoglycemic Agents Insulin Obesity Thiazolidinedione Creatinine medicine.diagnostic_test Pioglitazone business.industry General Medicine Fasting Overweight medicine.disease Impaired fasting glucose Treatment Outcome chemistry Uric acid Thiazolidinediones Lipid profile business Energy Intake medicine.drug |
| Zdroj: | Diabetes research and clinical practice. 75(1) |
| ISSN: | 0168-8227 |
| Popis: | Aim To evaluate the effect of a thiazolidinedione, pioglitazone, on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Methods A randomized, double-blind, placebo-controlled clinical trial was carried out in 18 overweight or obese patients with both impaired fasting glucose and impaired glucose tolerance. Pharmacological intervention consisted of an oral morning administration of pioglitazone (30 mg) or a placebo with a similar presentation for 30 days. Before and after the intervention, glucose, creatinine, lipid profile and uric acid concentrations were measured. To evaluate insulin secretion (early, late and total phases) and insulin sensitivity, a hyperglycemic-hyperinsulinemic clamp was also performed. Results There were significant reductions ( p = 0.008) in fasting insulin concentration (121 versus 45 pmol/l), late (565 versus 307 pmol/l) and total insulin secretion (474 versus 254 pmol/l), as well as, in 2 h postload glucose levels (9.7 versus 6.9 mmol/l, p = 0.028), with an increment in insulin sensitivity after pioglitazone administration (7.5 versus 9.9). Conclusion Pioglitazone administration during a period of 4 weeks decreased late and total insulin secretion phases, fasting insulin and 2 h postload glucose levels, and improved insulin sensitivity in patients with both impaired fasting glucose and impaired glucose tolerance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect